Apollo Q2 FY26 PAT rises 26% and revenue rises 13%

Pat Growth 25pctEbitda Margin ExpansionEmphasis Of MatterResults View source PDF Explain this filing

APOLLOHOSP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.8%Reaction day

₹7783.00

prior close

₹7789.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.0%-1.8% vs market

Hospital peers, median of 20sector+0.2%-2.0% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty 100 and 2.0 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.5

15m

-0.5

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.8-0.0-1.8+0.2-2.0

Next day

-3.2+0.3-3.5-1.2-2.0

-3.4+0.7-4.1-1.9-1.5

-3.6+1.3-4.9-1.7-1.9

-4.4+1.3-5.7-2.2-2.2

-4.7+1.4-6.1-2.4-2.3

-5.2+1.4-6.6-2.0-3.2

15d

-5.7+2.2-8.0-2.7-3.0

-8.8+1.0-9.8-5.1-3.7

-4.2+2.4-6.6-7.2+3.1

-7.2+1.3-8.5-11.8+4.6

UpDownMarket · Nifty 100Sector · Hospital peers, median of 20Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated Q2 FY26 revenue rose 13% year on year to Rs 6,304 crore, EBITDA rose 15% to Rs 941 crore and PAT rose 26% to Rs 477 crore. In H1, revenue reached Rs 12,146 crore, up 14%, while EBITDA and PAT rose 20% and 33% to Rs 1,793 crore and Rs 910 crore. The auditor gave an unmodified review but highlighted a land dispute at a subsidiary. The planned pharmacy and digital health business transfer also received Competition Commission approval.

Likely market impact

Strong profit growth and a wider operating margin support sentiment, but the subsidiary land dispute and pending business transfer remain execution risks.